About: Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article by Ghassan K Abou-Alfa et al published 5 July 2018 in The New England Journal of Medicine

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в липні 2018 (uk) im Juli 2018 veröffentlichter wissenschaftlicher Artikel (de) article by Ghassan K Abou-Alfa et al published 5 July 2018 in The New England Journal of Medicine (en)
publication date	wds:Q56373211-5ADBB172-1BAF-4534-A608-1F9D41FDA50E
publication date	2018-07-05 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q56373211-3C4D2B1A-C295-4A48-9E85-66096670A67B
language of work or name	English
cites work	wds:Q56373211-01C8EE72-0479-487A-A2B3-28C32994EBFB wds:Q56373211-08D299D0-1A9B-42C9-9424-3CA16800A887 wds:Q56373211-12CCB80C-9682-4DF5-A177-7D0E67D15F8E wds:Q56373211-20DA440D-016A-4A56-8F92-230D8714570E wds:Q56373211-22E74401-268D-4877-91E1-CC6A6021E7C2 wds:Q56373211-2898887F-5F35-4ACF-AC33-32F180296A8F wds:Q56373211-2C080A2D-651E-4559-AB2A-E34C733AC664 wds:Q56373211-2DFF44B9-BDAF-4970-9C5F-01B317CF9779 wds:Q56373211-46838AE0-3A93-4AB4-B8FC-0DA55AA44714 wds:Q56373211-57B8EC03-E408-4E07-A099-0B2ADE5CC750 wds:Q56373211-60225E01-D5BA-47DE-8117-657B31AC2C6E wds:Q56373211-60C380E7-946A-450B-BCCF-C1C9C5D8EB35 wds:Q56373211-6E88461A-9789-4728-8651-4B63544F2CC8 wds:Q56373211-730E7BD2-0A09-473A-B5E7-B4002384BD0A wds:Q56373211-75FE7551-CD72-40E5-864D-06B82AC34331 wds:Q56373211-7AF6F6BB-8C13-477D-8AA4-FAB08ADEBE3A wds:Q56373211-7FA58689-88CF-4E70-902A-B71A71B059FA wds:Q56373211-80824C1B-64D0-4017-9B9E-CE688198DD56 wds:Q56373211-8C684B93-5A57-427A-8905-6E01F8EA31F0 wds:Q56373211-9B419360-145C-4E3D-9178-4EBF75381A02 wds:Q56373211-A566BEDA-26C4-4A52-B36B-E3503B2B843D wds:Q56373211-AA5E96C1-D3CA-4E22-8CCC-85F11B2351B3 wds:Q56373211-ADA07715-9A70-4590-9931-40FF296A57B4 wds:Q56373211-B6DF00AC-8D80-439C-B6D3-2EFE4DC115BD wds:Q56373211-CD32F6EF-B736-4444-970C-37A3641B061A wds:Q56373211-D7F82B91-B92C-4471-B8E1-667FE297162E wds:Q56373211-DE4EF2B4-0009-4C15-8A27-CB04F5846BA6 wds:Q56373211-E114C9AF-F7CA-4A18-94ED-4139AEC5BAE0 wds:Q56373211-E62F3BC9-1653-4A6A-A899-BCDE48697FAE
cites work	Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors Targeting MET in cancer: rationale and progress Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Interim analysis: the alpha spending function approach. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. Sorafenib in advanced hepatocellular carcinoma Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma NCCN clinical practice guidelines in oncology: hepatobiliary cancers The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached? Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Axl Expression Stratifies Patients with Poor Prognosis after Hepatectomy for Hepatocellular Carcinoma Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study The Receptor Tyrosine Kinase AXL in Cancer Progression
author name string	wds:Q56373211-363D1C2D-EF02-49DE-8CD8-E98C2F78E867 wds:Q56373211-3785C4FC-D91A-442C-9C5C-576A3A1A3C77 wds:Q56373211-42AD6B9D-13B2-4FCD-9DB6-FF5C5A6C8631 wds:Q56373211-48747DF3-0F92-40A0-B509-9BA435D3D4DB wds:Q56373211-57EC1245-A65B-41D6-974B-73E08D84371C wds:Q56373211-5CAF6541-B10B-4F54-87E9-F75E1EC68FD1 wds:Q56373211-5E4D821A-1F8D-4F1D-931E-39F86047755E wds:Q56373211-69005D15-5135-4100-8AB9-04E07DD1C4EF wds:Q56373211-6CFCFC4F-ABB6-4BEA-8DEE-6AFBC40E1F93 wds:Q56373211-8CDEE964-0D5E-40C2-994A-F53E1C22D4A1 wds:Q56373211-A5BB69DC-43C5-48B7-A0AD-8C691A8B4851 wds:Q56373211-AEE38ABC-1755-4D26-8A79-A95B228DDA87 wds:Q56373211-B535ED62-ECA3-4FF6-9961-95AF427C7508 wds:Q56373211-BEE6CC62-921C-41D5-9274-F9919F88B433 wds:Q56373211-E265C0D8-B151-4645-A28E-18B08154BAA2 wds:Q56373211-E33AB917-12B5-4258-978D-A6100109F96F wds:Q56373211-EC640795-B0E7-42C8-B85B-4B34DE6B8165 wds:Q56373211-F6F70F4A-369C-4D4B-9A6B-C767A59F1B6E wds:Q56373211-F7BE5272-B4CD-44F3-BDE3-A422C3252F3E wds:Q56373211-FE95B102-5285-4573-97EC-AAF9D457145C
author name string	Alan P Venook Ann-Lii Cheng Stephen L Chan Robin K Kelley Ghassan K Abou-Alfa Tim Meyer Heinz-Josef Klümpen Jean-Frederic Blanc Luigi Bolondi Baek-Yeol Ryoo Irfan Cicin Colin Hessel Joong-Won Park

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 176 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software